Mithra Pharmaceuticals (MITPF) Stock Price, News & Analysis

Company Overview

Mithra Pharmaceuticals SA was a Belgian biotechnology company focused on women’s health. Founded in 1999 and headquartered in Liège, the company developed pharmaceutical products for contraception, menopause management and other gynecological conditions, with an emphasis on therapies based on estetrol (E4), a naturally occurring estrogen.

Mithra’s principal product platform centered on E4-based medicines. Its combined oral contraceptive, marketed as Nextstellis in the United States and Canada and as Drovelis in Europe and certain other markets, combines estetrol with drospirenone. The company also developed Donesta, an investigational hormone therapy intended to treat menopausal symptoms, along with other contraceptive and women’s health products.

Mithra pursued international commercialization primarily through licensing and distribution partnerships rather than relying solely on its own sales organization. Its products and development programs were directed toward markets in Europe, North America and other international regions. The company entered financial difficulties and insolvency proceedings in 2024, so its corporate and commercial activities may have subsequently changed.

Key Stats

• Today's Range: $6.75 to $6.75
• 50-Day Range: $6.75 to $6.75
• 52-Week Range: $6.75 to $7.75
• Volume: N/A
• Average Volume: 1,600 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MITPF
• CIK: N/A
• Web: www.mithra.com
• Phone: 32 4 349 28 22
• Fax: N/A
• Employees: 270
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A